Evidence map›Paper›PMID 41375077›Full record

ArticleCancers2025

CRISPR-Cas9 Genome and Double-Knockout Screening to Identify Novel Therapeutic Targets for Chemoresistance in Triple-Negative Breast Cancer.

Shuai Shao, Shangjia Li, Yang Huo, Shan Tang, Birkan Gökbağ, Kunjie Fan, Yirui Huang, Lingling Wang, Gregory Nagy, Jeffrey Parvin and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Shuai ShaoDepartment of Biomedical Informatics, College of Medicine, The Ohio State University, Columbus, OH 43210, USA.
Shangjia LiDepartment of Biomedical Informatics, College of Medicine, The Ohio State University, Columbus, OH 43210, USA.
Yang HuoDepartment of Biomedical Informatics, College of Medicine, The Ohio State University, Columbus, OH 43210, USA.
Shan TangDepartment of Biomedical Informatics, College of Medicine, The Ohio State University, Columbus, OH 43210, USA.ORCID 0000-0002-8224-2809
Birkan GökbağDepartment of Biomedical Informatics, College of Medicine, The Ohio State University, Columbus, OH 43210, USA.ORCID 0000-0002-9238-1650
Kunjie FanDepartment of Biomedical Informatics, College of Medicine, The Ohio State University, Columbus, OH 43210, USA.
Yirui HuangDepartment of Biomedical Informatics, College of Medicine, The Ohio State University, Columbus, OH 43210, USA.
Lingling WangDepartment of Biomedical Informatics, College of Medicine, The Ohio State University, Columbus, OH 43210, USA.
Gregory NagyDepartment of Biomedical Informatics, College of Medicine, The Ohio State University, Columbus, OH 43210, USA.
Jeffrey ParvinDepartment of Biomedical Informatics, College of Medicine, The Ohio State University, Columbus, OH 43210, USA.
Daniel StoverDivision of Medical Oncology, Department of Medicine, The Ohio State University, Columbus, OH 43210, USA.
Lijun ChengDepartment of Biomedical Informatics, College of Medicine, The Ohio State University, Columbus, OH 43210, USA.ORCID 0000-0002-6336-5416
Lang LiDepartment of Biomedical Informatics, College of Medicine, The Ohio State University, Columbus, OH 43210, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

CRISPR-Cas9genome screeningtriple-negative breast cancer

Identifiers

PMID41375077
PMCPMC12691371

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.